uniQure's (QURE) Gene Therapy for Huntington's Disease Advances with FDA Meeting

 uniQure (QURE) has scheduled a Type A meeting with the U.S. Food and Drug Administration to discuss the data package of their Biologics License Application. This meeting is a crucial step in the process of seeking accelerated approval for AMT-130, an investigational gene therapy aimed at treating Huntington's disease.

https://www.gurufocus.com/news/4103782/uniqures-qure-gene-therapy-for-huntingtons-disease-advances-with-fda-meeting